
Seasonal allergic rhinitis (SAR) is a common chronic inflammatory disease of the nasal mucosa that significantly affects patients' quality of life and represents a risk factor for the development of asthma. The pharmacy is often the patient's first point of contact with the healthcare system, placing the pharmacist in a key role in the early identification of the disease, recommending appropriate self-medication, and recognizing situations requiring medical evaluation. This article summarizes current recommendations for the treatment of seasonal allergic rhinitis, focusing on a rational stepwise approach to self-medication in the pharmacy, and provides practical guidelines for pharmaceutical practice.
OBJECTIVE:The study aims to substantiate the development of an oral dosage form for military medicine based on the API dimethylammonium 3-methyl-2-(2-((E)-styryl)quinazolin-4-ylthio)butanoate, which demonstrates antioxidant and hepatoprotective activity. The molecule's physicochemical properties and dissociation constant were evaluated. MATERIALS AND METHODS:Computer modelling was used to assess lipophilicity, physicochemical parameters, and ADME characteristics via the SwissADME service. Drug-likeness was evaluated according to Lipinski's Rule of Five. Conductometric studies of API solutions (0.0625-0.5 M) were performed with a Konduktometr N 5721 M to determine χ, λv, λ∞, α, and the dissociation constant (7.45 × 10-8-9.2 × 10-8). The ionization constant was used to calculate pK = 7.13, indicating the pH range of optimal absorption. RESULTS:ADME analysis showed high gastrointestinal absorption and suitable solubility, supporting the feasibility of an oral dosage form. Conductometric data confirmed the API to be a weak electrolyte with increasing dissociation at lower concentrations. The pK value suggests preferential absorption in the neutral to slightly alkaline environment of the small intestine. Considering its pharmacological activity, the API is promising for further development of tablets or capsules for military and clinical use. CONCLUSIONS:The findings justify designing a gastro-resistant oral dosage form ensuring API stability in gastric acid and efficient intestinal absorption. Such a form is particularly valuable for military medicine due to its stability, portability, and suitability for emergency and rehabilitation settings.
Tinea pedis (athlete's foot) is a superficial fungal skin infection caused by dermatophytes, most commonly the anthropophilic dermatophyte Trichophyton rubrum. Clinically, it is characterized mainly by scaling, erythema, and fissure formation, and it may present in three primary forms: interdigital, plantar, and vesiculobullous. The infection is often accompanied by mild pruritus; when fissures develop, burning and pain may also occur. Maceration, fissures, and desquamation of the stratum corneum in the interdigital spaces may serve as entry points for β-haemolytic streptococci, thereby increasing the risk of erysipelas. Another complication is the potential spread of infection to the nails, hands, groin, or other body sites. Tinea pedis is primarily indicated for topical antifungal therapy. Over-the-counter antifungal agents include imidazoles, allylamines, thiocarbamates, and undecylenic acid derivatives. Based on an analysis of clinical studies, their efficacy and duration of treatment have been compared.